DCTD

Across TCGA pan-cancer cohorts, DCTD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated DCTD data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher DCTD mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated DCTD expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, COAD, and GBM are the cancer types where DCTD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.529	0.335	.005	17	view →
COAD	DFS	Median	III,IV	0.832	1.000	.029	12	view →
GBM	DFS	Median	All	0.664	0.835	.010	7	view →
CCRCC	DFS	Quartile	II,III,IV	1.000	0.193	.036	2	view →
LSCC	OS	Tertile	All	1.000	0.918	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

DCTD–PDAC (DFS)

Open the PDAC breakdown →